For example, Asciminib53 (ABL001) is an allosteric inhibitor for chronic myeloid leukemia (CML) that locks BCR-ABL1 in an inactive conformation by binding to the myristoyl pocket (STAMP), overcoming drug-resistant mutations such as the T315I mutation. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.